CM
VRDN icon

Caption Management’s Viridian Therapeutics VRDN Stock Holding History

Caption Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$559K – 2068
2025
Q2 		$559K Buy
40,000
+7,300
+22% +$99.1K 0.01% 1085
2025
Q1 		$441K Sell
32,700
-71,900
-69% -$1.22M ﹤0.01% 1126
2024
Q4 		$2.01M Sell
104,600
-87,400
-46% -$1.9M 0.02% 687
2024
Q3 		$4.37M Buy
+192,000
New +$3.14M 0.07% 332
2024
Q2 		– Sell
-45,000
Closed -$788K – 1540
2024
Q1 		$788K Buy
+45,000
New +$872K 0.01% 790
2023
Q3 		– Sell
-92,200
Closed -$2.19M – 1570
2023
Q2 		$2.19M Buy
92,200
+42,200
+84% +$1.08M 0.04% 478
2023
Q1 		$1.27M Buy
+50,000
New +$1.6M 0.02% 569
2022
Q2 		– Sell
-36,000
Closed -$665K – 1861
2022
Q1 		$665K Hold
36,000
– – 0.01% 1092
2021
Q4 		$713K Hold
36,000
– – 0.01% 1156
2021
Q3 		$592K Buy
+36,000
New +$528K 0.01% 1173

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caption Management's VRDN Position: Q1 2026 in Review

Caption Management opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 45,127 shares worth $883K. The stake represents 0.01% of the portfolio and ranks #1062 among its holdings. This is a return to the name: Caption Management previously reported a position in VRDN as recently as Q3 2025.

Caption Management first reported a position in VRDN in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.09M in Q4 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Caption Management held 45,127 shares of Viridian Therapeutics worth $883K as of Q1 2026.
  • Viridian Therapeutics was a new Caption Management position in Q1 2026.
  • Viridian Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #1062 holding.
  • Caption Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • Caption Management's Viridian Therapeutics position peaked at $1.09M in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.